posted on 2013-06-21, 00:00authored byDa-Woon Jung, Woong-Hee Kim, Si-Hwan Park, Jinho Lee, Jinmi Kim, Dongdong Su, Hyung-Ho Ha, Young-Tae Chang, Darren R. Williams
Enolase is a component of the glycolysis
pathway and a “moonlighting”
protein, with important roles in diverse cellular processes that are
not related to its function in glycolysis. However, small molecule
tools to probe enolase function have been restricted to crystallography
or enzymology. In this study, we report the discovery of the small
molecule “ENOblock”, which is the first, nonsubstrate
analogue that directly binds to enolase and inhibits its activity.
ENOblock was isolated by small molecule screening in a cancer cell
assay to detect cytotoxic agents that function in hypoxic conditions,
which has previously been shown to induce drug resistance. Further
analysis revealed that ENOblock can inhibit cancer cell metastasis in vivo. Moreover, an unexpected role for enolase in glucose
homeostasis was revealed by in vivo analysis. Thus,
ENOblock is the first reported enolase inhibitor that is suitable
for biological assays. This new chemical tool may also be suitable
for further study as a cancer and diabetes drug candidate.